On Oct.28, Principal Investigator PAN Liqiang, College of Pharmaceutical Sciences Zhejiang University, was selected by MIT Technology Review as one of the 35 Innovators under the age of 35 in the Asia-Pacific region for his basic and translational research in the field of tumor immunobiologic drugs.

Dr. PAN's research focuses on unveiling the molecular mechanism of TNFR activation signal transduction signaling, and the development of novel multi-functional ligand (e.g., TRAIL, APRIAL) or antibody derivatives for tumor immunotherapy via leveraging the signaling pathways of death receptors (e.g., DR5) or immunoreceptors (e.g., 4-1BB, OX40) from TNFR superfamily. He has also co-invented a revolutionary Nucleic acid–mediated protein–protein assembly (NAPPA) technology that allows pre-storage of individual antibody fragments (nanobody, scFv, and Fab) targeting different antigens, and their self-assembly “on the fly” to form multi-specific antibodies of any order of specificity during a personalized cancer treatment.